Kornimate/medical-research-clean huggingface dataset:
iron bioavailability from cubes

Conditions: Iron Deficiency

Summary: iron deficiency is a highly prevalent nutrient deficiency which is a public health problem, especially in developing countries. there are several strategies to correct iron deficiency in populations: besides supplementation with tablets, one of the most sustainable and effective strategies on medium term has been iron fortification, the addition of iron to regularly consumed foods. in fortification, the chemical nature of the compound to be added plays an important role: depending on the compound sensory qualities of the fortified foods can vary as well as the iron absorption. iron pyrophosphate (fepp) and ferrous sulfate (feso4) are two commonly used iron fortification compounds in foods such as rice, breakfast cereals, pasta, flour and others. we want to test the effect of addition a food stabilizer on the absorption of ferric pyrophosphate (fepp) and ferrous sulfate (feso4) when added to bouillon, as was recently suggested by in vitro experiments in the laboratory.


Eligibility criteria:
inclusion criteria: * age \> 18 and \< 40 years at screening; * body weight \<65 kg; * apparently healthy: no medical conditions which might affect study measurements (judged by study physician); * with low iron stores (serum ferritin \<15µg/l); * reported intense sporting activities ≤10h/w; * reported alcohol consumption ≤14 units/w; * currently not smoking and being a non-smoker for at least six months and no reported use of any nicotine containing products in the six months preceding the study and during the study itself; * willing and able to participate in the study; * having given a written informed consent. exclusion criteria: * being an employee of unilever or the laboratory of human nutrition of the eth zürich; * blood donation or significant blood loss over the past 6 months; * reported use of any medically- or self-prescribed diet; * use of medication (except oral contraceptives) * use of vitamin or mineral supplements and unwillingness to discontinue their use two weeks prior the study and during the study; * smoking or consuming tobacco in any form, and/or was smoking or consuming tobacco in any form for 6 months preceding the study and/or will be smoking or consuming tobacco in any form, during the study; * is pregnant or will be planning pregnancy during the study period; * is lactating or has been lactating in the 6 weeks before pre-study investigation and/or during the study period; * known gastrointestinal or metabolic disorders; * moderate or severe anemia defined as hb \< 90 g/l. * participation in another clinical trial during the last 30 days prior to the beginning of the study.

Keywords: iron deficiency iron fortification
effect of progressive muscle relaxation on anxiety and comfort

Conditions: Muscle Relaxation; Coronary Artery Disease

Summary: this study aimed to examine the effect of relaxation exercise applied to patients who will undergo elective coronary angiography (cag) for the first time, on their vital signs, anxiety and comfort levels. the main questions it aims to answer are: 1. does progressive relaxation exercises affect cag patients' vital signs. 2. does progressive relaxation exercises affect cag patients' anxiety levels. 3. does progressive relaxation exercises affect cag patients' comfort levels. researchers will compare the intervention group with the control group to see if relaxation exercise is effective. before coronary angiography, patients will undergo a relaxation exercise once. vital signs, comfort and anxiety level will be evaluated before and after angiography.

coronary angiography (cag) is considered the "gold standard" in determining coronary anatomy. and it is used very frequently in the diagnosis and treatment of coronary artery disease. cag, which is an invasive procedure, causes anxiety in patients undergoing the procedure. anxiety leads to negative consequences in vital signs such as increased blood pressure, pulse and respiration rate, and pain intensity. pain, anxiety and many factors that develop due to invasive procedures such as angiography also reduce the comfort level of patients. reducing anxiety and pain, preventing negativities in vital signs, and increasing comfort contribute to the success of the procedure, the patient's level of well-being, and satisfaction with health care services. this study aimed to determine the effect of progressive relaxation exercise on patients' vital signs, anxiety and comfort levels in patients undergoing angiography.

Eligibility criteria:
inclusion criteria: * undergo cag for the first time * has a chest score of 5 or less on the pain scale * has no history of mental disorder according to medical records * is able to communicate exclusion criteria: * admission to the intensive care unit after the cag procedure * starting analgesic or perlinganit infusion * wanting to quit the research

Keywords: anxiety coronary angiography patient comfort progressive relaxation exercise vital signs
investigation of the influence of careless™, a mangifera indica fruit powder, on microcirculation and endothelial function

Conditions: Microcirculation; Metabolism; Cardiovascular Disease

Summary: investigation of the acute effects of a single dose of careless™, a mangifera indica fruit powder on cutaneous microcirculation and endothelial function.


Eligibility criteria:
inclusion criteria: * subject is able and willing to sign the informed consent form prior to screening evaluations * subject is in good physical and mental health as established by medical history, physical examination, electrocardiogram, vital signs, results of biochemistry and haematology * healthy normal skin condition at the forearm * bmi: 19-30 kg/m2 * female * age ≥ 40 and ≤ 70 years * nonsmoker * able and willing to follow the study protocol procedures exclusion criteria: * relevant history, presence of any medical disorder or chronic intake of medication/dietary supplements (e.g. polyphenols, l-arginine, niacin, medication of haemodilution, blood flow stimulating products like aspirin) potentially interfering with this study at screening * for this study clinically relevant abnormal laboratory, vital signs or physical findings at screening * atopic dermatitis or affected skin at the forearm * regular consumption of caffeine \> 275 mg (equivalent to 3-4 cups of coffee or 9 cups of black tea) * change of dietary habits within the 2 weeks prior to screening (for instance start of a diet high in vegetables and fruits (≥ 5 portions per day)) * diet high in vegetables and fruits ≥ 5 portions per day * participants anticipating a change in their lifestyle or physical activity levels since this may also influence the results * subjects not willing to avoid polyphenol rich foods and abstain from beverages containing caffeine the day prior to visit 1 and 2 * subjects not willing to abstain from intake of analgesic medication (e.g. aspirin) 24 hours prior to and during visit 1 and 2 * sunbathing or the use of sun-beds 2 weeks prior to study days * injury on the finger, influencing the endopat™ measurement * subjects with history of drug, alcohol or other substances abuse, or other factors limiting their ability to co-operate during the study * known hypersensitivity to the study product or to single ingredients * pregnant subject or subject planning to become pregnant during the study; breast-feeding subject. * known hiv-infection * known acute or chronic hepatitis b and c infection * blood donation within 4 weeks prior to visit 1 or during the study * subject involved in any clinical or food study within the preceding month

Keywords: microcirculation endothelial function metabolism cardiovascular disease human study healthy subjects mangifera indica careless
protecting pregnant women from infectious diseases

Conditions: Influenza; Pertussis

Summary: the primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion package implemented in the obstetric setting on increasing the likelihood that a pregnant woman in georgia will receive an influenza and/or pertussis vaccine.

the primary research aim of this project is to test the effectiveness of a comprehensive, evidence-based vaccine promotion package implemented in the obstetric setting on increasing the likelihood that a pregnant woman in georgia will receive an influenza vaccine and/or tdap vaccine before delivery. a secondary research aim assesses whether the comprehensive package improves maternal knowledge, attitudes, and beliefs regarding maternal and infant vaccination. the intervention package will include evidence-based components aimed at the practice-level, provider-level, and patient level and will be tested through a cluster-randomized trial design. the primary outcome measure is influenza vaccine receipt during pregnancy. the secondary outcomes include 1) receipt of pertussis (tdap) vaccination during pregnancy, and 2) changes in maternal knowledge, attitudes and beliefs regarding maternal and infant vaccination. the primary hypothesis is that implementation of a comprehensive vaccine promotion package in the obstetric setting will increase the likelihood that a pregnant woman receives an influenza and/or pertussis vaccination.

Eligibility criteria:
inclusion criteria: * between the ages of 18 - 50 * currently pregnant * unvaccinated with 2012 - 2013 seasonal influenza vaccine * unvaccinated with tdap vaccine during current pregnancy exclusion criteria: * under 18 years of age or over 50 * not currently pregnant * previous receipt of 2012 - 2013 seasonal influenza vaccine * previous receipt of tdap vaccine during current pregnancy * does not speak english

Keywords: influenza pertussis vaccination
reconstruction technology to auxiliary diagnosis and guarantee patient privacy

Conditions: 3D-reconstruction; Patient Privacy; Deep Learning; Digital Medicine

Summary: medical data that contain facial images are particularly sensitive as they retain important personal biometric identity, privacy protection. we developed a novel technology called "digital mask" (dm), based on real-time three-dimensional (3d) reconstruction and deep learning algorithm, to extract disease-relevant features but remove patient identifiable features from facial images of patients.


Eligibility criteria:
inclusion criteria: * the quality of facial images should be clinically acceptable.
precision medicine in cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy; Sudden Cardiac Death

Summary: this is a retrospective cohort study of pediatric hypertrophic cardiomyopathy (hcm) patients using chart and registry review methodology. the studies objective is to develop and validate a sudden cardiac death (scd) risk calculator that is age-appropriate for children with hcm that includes clinical and genetic factors.


Eligibility criteria:
inclusion criteria: * phenotype-positive patients diagnosed with hypertrophic cardiomyopathy * phenotype-negative, genotype positive patients considered at risk for developing hypertrophic cardiomyopathy exclusion criteria: * neuromuscular, metabolic, syndromic (other than noonan syndrome and related ras-opathies) or endocrine (including infants of diabetic mothers) causes of hcm * (other treatable causes of left ventricular hypertrophy (systemic hypertension, anatomic defects causing left ventricular outflow tract obstruction e.g. aortic stenosis, subas, subaortic membrane, coarctation)

Keywords: pediatric risk prediction
proprioceptive stimulation with manual bilateral rhythmic exercise in post-stroke patients

Conditions: Stroke; Hemiparesis

Summary: the purpose of this study is to evaluate the effect of the repetitive proprioceptive bilateral stimulation for the early recovery of the voluntary muscle contraction in stroke patients.

the central nervous system (cns) has plastic properties allowing its adaptation through development. these properties are still maintained in the adult age and potentially activated in case of brain lesion. in the present study authors hypothesized that a significant recovery of voluntary muscle contraction in post stroke patients experiencing severe upper limb paresis can be obtained, when proprioceptive based stimulations are provided. the proprioceptive based training (pbt) aims to stimulate the emergence of voluntary contraction and to foster motor recovery. it is based on motor learning principles, such as the repetition of tasks with concurrent use of feedbacks. the proposed concept is based on the concurrent repetitions of movements performed with the non-affected limb and with the affected one, passively mobilized by physiotherapist in charge of guaranteeing the optimal kinematic execution.

Eligibility criteria:
inclusion criteria: 1. time since stroke up to 6 months, 2. presence of the upper limb plegia (0 point according to the medical research council scale), 3. passive range of motion (rom) completely free, 4. absence of primary joint trauma of the wrist, elbow and shoulder, exclusion criteria: 1. increased muscle tone (score higher than 1 point in modified ashworth scale), 2. apraxia (de renzi test \< 62 points), 3. global sensory aphasia (clinical notes), 4. neglect (clinical notes), 5. cognitive impairments (mini mental state examination test \< 24 points) , 6. severe sensitivity disorders ( \< 1 point in items shoulder, elbow, wrist and thumb at the proprioceptive sensitivity section of the fugl-meyer scale), 7. stroke lesion located in the cerebellum (clinical notes).

Keywords: stroke neurorehabilitation proprioceptive training bilateral arm training intracortical inhibition
the efficacy and complication of gentamicin nasal irrigation in chronic rhinosinusitis and recurrent sinusitis

Conditions: Rhinosinusitis

Summary: topical antibiotic therapy in patients with refractory sinusitis has been shown to improve symptoms, quality of life, and mucosal aspect. in pediatrics allergy clinic at siriraj hospital since 2006 use gentamicin nasal irrigation for chronic rhinosinusitis.there have been no prospective studies in gentamicin irrigation in chronic rhinosinusitis.

chronic rhinosinusitis (crs) is characterized by symptoms \> 12 weeks.two or more symptoms one of which should be either nasal blockage /obstruction/congestion or nasal discharge (anterior/posterior nasal drip): facial pain/pressure reduction or loss of smell). mainstay of treatment are medical and surgical treatment ( atb, adenoidectomy, ess) adjunctive treatment : normal saline nasal irrigation, nasal corticosteroids, nasal decongestants, mucolytics. nasal lavage with mupirocin represent an effective and well tolerated alternative treatment of surgically recalcitrant chronic rhinosinusitis. gentamicin irrigation should be helpful in chronic rhinosinusitis.

Eligibility criteria:
inclusion criteria: 1. chronic rhinosinusitis and/or recurrent acute/subacute sinusitis patients who were followed in pediatrics allergy clinic at siriraj hospital between december 4, 2012, and december 3, 2016 exclusion criteria: 1. patients who used antibiotic prophylaxis within within 1 year before and 6 months after started gentamicin nasal irrigation 2. patients received ivig within 1 year before and 6 months after started gentamicin nasal irrigation 3. patients received it within 1 year before and 6 months after started gentamicin nasal irrigation 4. patients underwent endoscopic sinus surgery within 1 year before and 6 months after started gentamicin nasal irrigation 5. patient who have mental retardation 6. patient who have aminoglycosides hypersensitivity reactions 7. pregnancy women and lactation period 8. patient who have abnormal hearing test before started gentamicin nasal irrigation 9. patient who have chronic rhinosinusitis with nasal polyp
treatment of olfactory dysfunction using vagus nerve stimulation

Conditions: Hyposmia

Summary: hyposmia, a reduced sense of smell, is commonly linked to viral infections like covid-19. currently, the sole recommended treatment is olfactory training, a method that is both time-intensive and limited in its effectiveness. our team has previously evaluated a new type of olfactory training using nasal inserts that show increased adherence to training (compared to standard olfactory training using common household odors) but with similar treatment effect. the investigators recently demonstrated that brief transcutaneous vagus nerve stimulation (vns) in the cymba conchae region affected participants olfactory abilities but only when a stimulation frequency relevant to olfactory bulb processing frequencies was used. the notion that vns might modulate olfactory functions stems from findings in rats where vns of the cervical nerve inhibited neurons within the periglomerular layers of the olfactory bulb. although there is no known monosynaptic connection between the vagus nerve and the olfactory system in humans, vns activates areas with mono-synaptic connections to the olfactory bulb, such as amygdala, hippocampus, and the hypothalamus. given that vns modulates the olfactory bulb in rats and our treatment protocol modulate olfactory functions in humans, the investigators hypothesize that vns, when paired with olfactory training, will enhance olfactory functions in patients with hyposmia.

participants with hyposmia will be recruited and randomly assigned to one of two treatment groups. one group will engage in olfactory training using nasal inserts while the other will use olfactory training with nasal inserts along with vns. both interventions will take place at home, monday through friday, over a two-month period. to evaluate the outcomes, subjective and objective measures of olfactory function will be collected before, during, and after the treatment, along with assessments of quality of life and overall well-being. treatment adherence will also be evaluated at the end of treatment.

Eligibility criteria:
inclusion criteria: * correct age (18-65) * physically and cognitively capable of participating in the study * having appropriate olfactory screening test scores (hyposmic) exclusion criteria: * history of heart conditions * individuals with other diagnoses that could affect the study results

Keywords: vns hyposmia olfaction olfaction disorders sensation disorders vagus nerve
human fibrinogen concentrate in pediatric cardiac surgery

Conditions: Hypofibrinogenemia; Afibrinogenemia; Bleeding Disorders

Summary: the goal of the study is to determine whether the use of human fibrinogen concentrate (riastap) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.

the goal of the study is to determine whether the use of human fibrinogen concentrate (riastap) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass. riastap will be administered after termination of cardiopulmonary bypass (cpb) at a dose of 70 mg/kg, in a prospective, randomized, controlled study. we hypothesize that the administration of riastap in this manner will reduce peri-operative bleeding and transfusion requirements.

Eligibility criteria:
inclusion criteria: * neonatal and infant cardiac patients presenting for open-heart surgery at nicklaus children's hospital will be eligible for enrollment in the study. exclusion criteria: * patients who fall outside of the age range for the study will be excluded. patients known to have had an anaphylactic or severe reaction to the drug or its components will not be enrolled. at the time of the rewarming rotem, any patient with a fibtem mcf \> 15mm, will be excluded.

Keywords: cbp, congenital heart defects, cardiopulmonary bypass
proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa

Conditions: Hidradenitis

Summary: this is a parallel, phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (pk), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (hs). the purpose of this study is to measure standardized clinician reported and participant-reported outcomes (clinro and pro), safety, and drug concentration. an optional long-term extension (lte) period will assess chronic safety and efficacy over an additional 80 weeks of amlitelimab treatment. study details include: * the study duration will be up to 116 weeks, including a 4-week screening period, a 16-week double-blind treatment period (dbt), an optional 80-week lte period and a 16-week post-treatment follow-up period. * all participants who complete the 16-week dbt period will be offered entry into an optional lte. * participants who do not wish to enter the optional lte period or who stop treatment prior to week 16 (visit 6) or stop investigational medicinal product (imp) administration prior to completing the lte period will proceed into the 16-week post-treatment follow-up period. * the number of planned in clinic visits will be up to six during the dbt period with an additional nine during the lte period, plus one post-treatment follow-up end-of-study visit. up to 11 optional in clinic visits are allowed for participants who do not wish to self-administer imp between scheduled in clinic visits during the lte period.

the study duration per participant will be up to 116 weeks.

Eligibility criteria:
inclusion criteria: * participant must be 18 (or country's age of majority if \>18) years to 70 years of age inclusive, at the time of signing the informed consent. * participants with a history of signs and symptoms consistent with hs for at least 1 year prior to baseline. * participants must have hs lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), 1 of which must be hurley stage ii or hurley stage iii. * participant must have had an inadequate response to at least a 12-week trial of an oral antibiotic for treatment of hs exclusion criteria: * participants with a diagnosis of inflammatory conditions other than hs (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, multiple sclerosis, behcet's disease, sarcoidosis, etc) * any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of hs the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial